Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Eli Lilly is one of the top growth stocks in the pharmaceutical industry. Vertex Pharmaceuticals boasts multiple growth ...

The stock's fall snapped a four-day winning streak.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...